Straits Times Index
3,199.01 +25.19 (+0.79%) S&P 500
4,514.70 +28.24 (+0.63%) Dow
35,436.70 +178.09 (+0.51%) Nasdaq
15,107.79 +85.98 (+0.57%) BTC-USD
62,764.82 +856.45 (+1.38%) CMC Crypto 200
1,459.11 -4.25 (-0.29%)
Clovis Oncology, Inc. (CLVS)
- Business Wire
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
BOULDER, Colo. & MUNICH, October 19, 2021--Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITM’s therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a. 177Lu), EndolucinBeta®, for use in the clinical development of FAP-2286, Clovis’ fibroblast activation protein (FAP)-targeting therapeutic candidate. FAP-2286 is the firs
- Zacks
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
- Business Wire
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
BOULDER, Colo., October 07, 2021--Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
